Long-term immunity and the effect of one or two booster doses with a lyophilized human rabies vaccine (human diploid cells) at 10 years post primary vaccination in China

References

• Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, Barrat J, Blanton JD, Briggs DJ, Cleaveland S, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709. doi:10.1371/journal.pntd.0003709.
   PubMed Web of Science ®Google Scholar
• WHO fact sheets on rabies 2020. [accessed 2020 Apr]. https://www.who.int/en/news-room/fact-sheets/detail/rabies .
   Google Scholar
• WHO. Rabies vaccines: WHO position paper, April 2018 - recommendations. Vaccine. 2018 Sept 5;36(37):5500–03. doi:10.1016/j.vaccine.2018.06.061.
   PubMed Web of Science ®Google Scholar
• Jackson AC. Human rabies: a 2016 update. Curr Infect Dis Rep. 2016;18(11):38. doi:10.1007/s11908-016-0540-y.
   PubMed Web of Science ®Google Scholar
• Ramezankhani R, Shirzadi MR, Ramezankhani A, Poor Mozafary J. A comparative study on the adverse reactions of purified chick embryo cell vaccine (PCECV) and purified vero cell rabies vaccine (PVRV). Arch Iran Med. 2016;19(7):502–07.
   PubMed Web of Science ®Google Scholar
• Shi N, Zhang Y, Zheng H, Zhu Z, Wang D, Li S, Li Y, Yang L, Zhang J, Bai Y, et al. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects. Hum Vaccines Immunother. 2017;13(6):1–8. doi:10.1080/21645515.2017.1279770.
   Web of Science ®Google Scholar
• Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M. Post-marketing surveillance of human rabies diploid cell vaccine (Imovax) in the vaccine adverse event reporting system (VAERS) in the United States, 1990–2015. PLoS Negl Trop Dis. 2016;10(7):e0004846. doi:10.1371/journal.pntd.0004846.
   PubMed Web of Science ®Google Scholar
• WHO. WHO position on rabies vaccine. WHO Drug Information. 2002:16(1).
   Google Scholar
• Bahmanyar M, Fayaz A, Nour-Salehi S, Mohammadi M, Koprowski H. Successful protection of humans exposed to rabies infection. Post-exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. 1976. Wilderness Environ Med. 2000;11(1):42–46. doi:10.1580/1080-6032(2000)011[0042:PTWTNH]2.3.CO;2.
   PubMed Web of Science ®Google Scholar
• Tsiang H. Rabies vaccines: a review of progress towards improved efficacy and safety. BioDrugs. 1998;10(4):317–28. doi:10.2165/00063030-199810040-00006.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wu X, Cai Y, Cao S, Zhu X, Lv Q, Chen H, Shi L, Li J, Wang X, et al. Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial. Hum Vaccines Immunother. 2019;15(4):828–33. doi:10.1080/21645515.2018.1549450.
   PubMed Web of Science ®Google Scholar
• Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand. 1979 July;7(3):213–20. doi:10.1016/S0092-1157(79)80024-4.
   PubMedGoogle Scholar
• Organization WH. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. 1997.
   Google Scholar
• Organization WH. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser, 2013.
   Google Scholar
• Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L, et al. Immunogenicity and safety of subunit plague vaccine: a randomized phase 2a clinical trial. Hum Vaccines Immunother. 2016;12(9):2334–40. doi:10.1080/21645515.2016.1175261.
   PubMed Web of Science ®Google Scholar
• Thraenhart O, Kreuzfelder E, Hillebrandt M, Marcus I, Ramakrishnan K, Fu ZF, Dietzschold B. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol. 1994;71(3):287–92. doi:10.1006/clin.1994.1088.
   PubMedGoogle Scholar
• Kuwert EK, Marcus I, Hoher PG. Neutralizing and complement-fixing antibody responses in pre- and post-exposure vaccinees to a rabies vaccine produced in human diploid cells. J Biol Stand. 1976;4(4):249–62. doi:10.1016/S0092-1157(76)80010-8.
   PubMedGoogle Scholar
• Rosanoff E, Tint H. Responses to human diploid cell rabies vaccine: neutralizing antibody responses of vaccinees receiving booster doses of human diploid cell rabies vaccine. Am J Epidemiol. 1979;110(3):322–27. doi:10.1093/oxfordjournals.aje.a112817.
   PubMed Web of Science ®Google Scholar
• Mclean HQ, World Health Organization. The immunological basis for immunization series: module 17: rabies. 2011.
   Google Scholar
• Horman JT, Rullan JV, Myers RA, Bond JO, Israel E, Joseph JM. Antibody response after a two-year intradermal booster of rabies human diploid cell vaccine. J Am Vet Med Assoc. 1987;191:185–87.
   PubMed Web of Science ®Google Scholar
• Gherardin AW, Scrimgeour DJ, Lau SC, Phillips MA, Kass RB. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine. J Travel Med. 2001;8(3):122–26. doi:10.2310/7060.2001.24445.
   PubMed Web of Science ®Google Scholar
• Strady A, Lang J, Lienard M, Blondeau C, Jaussaud R, Plotkin S. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis. 1998;177(5):1290–95. doi:10.1086/515267.
   PubMed Web of Science ®Google Scholar
• Kessels JA, Recuenco S, Navarro-Vela AM, Deray R, Vigilato M, Ertl H, Durrheim D, Rees H, Nel LH, Abela-Ridder B, et al. Pre-exposure rabies prophylaxis: a systematic review. Bull World Health Organ. 2017;95(3):210–9C. doi:10.2471/BLT.16.173039.
   PubMed Web of Science ®Google Scholar